Annexon highlights pivotal data on first potential targeted therapy for guillain-barrÉ syndrome (gbs) and showcases new gbs education campaign at american academy of neurology (aan) 2025 annual meeting

Oral presentation features phase 3 data showing rapid recovery and durable benefit of tanruprubart (formerly anx005) on clinically meaningful measures across multiple stages of gbs

ANNX Ratings Summary

ANNX Quant Ranking